BETA
BETA
EyePoint Pharmaceuticals
EYPT68
$9.71arrow_drop_up2.64%$0.25
EYPT68
$9.71
arrow_drop_up2.64%Performance History
| Key Stats | |
|---|---|
| Open | $9.72 |
| Prev. Close | $9.46 |
| EPS | -1.81 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 9.44 | 9.90 |
| 52 Week Range | 5.67 | 30.99 |
| Ratios | |
|---|---|
| EPS | -1.81 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
Correlated Companies
About EyePoint Pharmaceuticals (EYPT)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jay S. Duker M.D.
- Headquarters
- Watertown
- Employees
- 144
- Exchange
- NASDAQ
Keep an eye on EyePoint Pharmaceuticals
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is EyePoint Pharmaceuticals 's (EYPT) price per share?
The current price per share for EyePoint Pharmaceuticals (EYPT) is $9.71. The stock has seen a price change of $0.25 recently, indicating a 2.64% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for EyePoint Pharmaceuticals (EYPT)?
For EyePoint Pharmaceuticals (EYPT), the 52-week high is $30.99, which is 219.16% from the current price. The 52-week low is $5.67, the current price is 71.25% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is EyePoint Pharmaceuticals (EYPT) a growth stock?
EyePoint Pharmaceuticals (EYPT) has shown an average price growth of 0.41% over the past three years. It has received a score of 89 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying EyePoint Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is EyePoint Pharmaceuticals (EYPT) stock price performance year to date (YTD)?
As of the latest data, EyePoint Pharmaceuticals (EYPT) has a year-to-date price change of -56.88%. Over the past month, the stock has experienced a price change of 17.55%. Over the last three months, the change has been -39.91%. Over the past six months, the figure is -61%. Looking at a longer horizon, the five-year price change stands at -32.1%.
help
Is EyePoint Pharmaceuticals (EYPT) a profitable company?
EyePoint Pharmaceuticals (EYPT) has a net income of -$70.8M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 89.93% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -285.19% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $46.02M, with a revenue growth rate of 11.14%, providing insight into the company's sales performance and growth. The gross profit is $41.39M. Operating income is noted at -$73.66M. Furthermore, the EBITDA is -$84.97M.
help
What is the market capitalization of EyePoint Pharmaceuticals (EYPT)?
EyePoint Pharmaceuticals (EYPT) has a market capitalization of $487.51M. The average daily trading volume is 795.01K, indicating the stock's liquidity and investor engagement.
News
6/19/2024
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
CONFERENCE CALLS/ WEBCASTS
CLINICAL STUDY
6/18/2024EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
MANAGEMENT STATEMENTS
6/17/2024EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CALENDAR OF EVENTS
CONFERENCE CALLS/ WEBCASTS
6/5/2024EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
NEWS
PRICE TARGET
MARKETS
TRADING IDEAS
5/13/2024Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
ANALYST RATINGS
5/7/2024Deep Dive Into EyePoint Pharmaceuticals Stock: Analyst Perspectives (4 Ratings)
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.